Congenital Toxoplasmosis in France and the United States: One Parasite, Two Diverging Approaches
- PMID: 28207736
- PMCID: PMC5312802
- DOI: 10.1371/journal.pntd.0005222
Congenital Toxoplasmosis in France and the United States: One Parasite, Two Diverging Approaches
Conflict of interest statement
FP runs reference centers for toxoplasmic serology funded respectively by Abbott and Siemens companies. JGM is Director of Palo Alto Medical Foundation Toxoplasmosis Serology Laboratory.
References
-
- McLeod R, Boyer K, Karrison T, Kasza K, Swisher C, Roizen N, et al. Outcome of treatment for congenital toxoplasmosis, 1981–2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2006;42: 1383–1394. - PubMed
-
- Wallon M, Peyron F, Cornu C, Vinault S, Abrahamowicz M, Kopp CB, et al. Congenital toxoplasma infection: monthly prenatal screening decreases transmission rate and improves clinical outcome at age 3 years. Clin Infect Dis Off Publ Infect Dis Soc Am. 2013;56: 1223–1231. - PubMed
-
- Tourdjman M, Tchéandjieu C, De Valk H, Goulet V, Le Strat Y. Toxoplasmose chez les femmes enceintes en France: évolution de la séroprévalence et des facteurs associés entre 1995 et 2010, à partir des Enquêtes nationales périnatales. English translation: Toxoplasmosis among pregnant women in France: trends in seroprevalence and associated factors between 1995 and 2010. Bull Epidemiol Hebd 2015: 264–72.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
